Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) Products under Development by Stage of Development | 8 | 1 |
| Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) Products under Development by Therapy Area | 9 | 1 |
| Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) Products under Development by Indication | 10 | 1 |
| Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) Products under Development by Companies | 13 | 2 |
| Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) Therapeutics Assessment | 15 | 7 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 2 |
| Assessment by Route of Administration | 18 | 2 |
| Assessment by Molecule Type | 20 | 2 |
| Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) Companies Involved in Therapeutics Development | 22 | 9 |
| AngioChem Inc. | 22 | 1 |
| ArmaGen Inc. | 23 | 1 |
| Bioasis Technologies Inc. | 24 | 1 |
| Green Cross Corporation | 25 | 1 |
| JCR Pharmaceuticals Co., Ltd. | 26 | 1 |
| Laboratorios Del Dr. Esteve S.A. | 27 | 1 |
| RegenxBio Inc. | 28 | 1 |
| Sangamo BioSciences, Inc. | 29 | 1 |
| Shire Plc | 30 | 1 |
| Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) Drug Profiles | 31 | 16 |
| AGT-182 Drug Profile | 31 | 2 |
| EGT-301 Drug Profile | 33 | 1 |
| idursulfase Drug Profile | 34 | 2 |
| idursulfase beta Drug Profile | 36 | 2 |
| JR-032 Drug Profile | 38 | 1 |
| JR-141 Drug Profile | 39 | 1 |
| MTf-I2S Drug Profile | 40 | 1 |
| MTfp-I2S Drug Profile | 41 | 1 |
| Recombinant Iduronate 2-Sulfatase Replacement for Mucopolysaccharidosis II Drug Profile | 42 | 1 |
| RGX-121 Drug Profile | 43 | 2 |
| SB-913 Drug Profile | 45 | 2 |
| Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) Featured News &Press Releases | 47 | 11 |
| Jul 14, 2016: ArmaGen Presents Data from First Cohort of Phase 1/2a of AGT-182 for Treatment of Hunter Syndrome | 47 | 1 |
| Jul 05, 2016: REGENXBIO Provides Update On Gene Therapy Development Program RGX-121 | 48 | 1 |
| Jun 20, 2016: Sangamo BioSciences Announces FDA Clearance of Investigational New Drug Application for ZFN-Mediated Genome Editing Treatment of MPS II | 48 | 1 |
| Apr 19, 2016: Preclinical Data from REGENXBIO s RGX-121 Gene Therapy Program to be Presented at the American Society of Gene &Cell Therapy 19th Annual Meeting | 49 | 1 |
| Feb 25, 2016: ESTEVE Provides Update On EGT-301 For Hunter Syndrome | 50 | 1 |
| Jul 31, 2015: biOasis Announces the Successful Delivery to the CNS of an Enzyme used to Treat Hunter Syndrome | 51 | 1 |
| Jun 23, 2015: ACTSI-supports first-in-man clinical trial for Hunter syndrome at Emory University Hospital | 51 | 1 |
| Jun 15, 2015: ArmaGen Achieves Clinical Milestone in Hunter Syndrome Collaboration with Shire | 52 | 1 |
| Mar 10, 2015: PacificGMP and ArmaGen Announce Successful Manufacture of ArmaGen's investigational enzyme replacement therapy, AGT-182, for Phase 1 Clinical Trial | 53 | 1 |
| Jan 26, 2015: Shire's Investigational SHP609, idursulfase-IT, Receives FDA Fast Track Designation for the Treatment of Neurocognitive Decline Associated with Hunter Syndrome | 54 | 1 |
| Dec 11, 2014: ArmaGen Announces FDA Acceptance of IND Application for AGT-182 for the Treatment of Hunter Syndrome | 54 | 1 |
| Sep 18, 2014: biOasis Initiates MPS II Study with Renowned Lysosomal Storage Disease Expert Dr. Maurizio Scarpa and The Brains for Brain Foundation | 55 | 1 |
| Jun 17, 2014: ArmaGen Receives Notice of Allowance for U.S. Patent Covering Novel Investigational Therapy for Hunter Syndrome | 56 | 1 |
| Oct 02, 2013: Green Cross Exports Orphan Disease Drug Hunterase to Algeria | 56 | 1 |
| Jul 18, 2013: ARMAGEN Receives US Orphan Designation For Lead Product AGT-182 | 57 | 1 |
| Appendix | 58 | 2 |
| Methodology | 58 | 1 |
| Coverage | 58 | 1 |
| Secondary Research | 58 | 1 |
| Primary Research | 58 | 1 |
| Expert Panel Validation | 58 | 1 |
| Contact Us | 58 | 1 |
| Disclaimer | 59 | 1 |